Table 3.
All (n = 48) | Survivors (n = 14) | Non-survivors (n = 34) | p-value* | |
---|---|---|---|---|
LL pre-ECMO (mmol/l) | 10.9 ± 5.4 | 7.6 ± 2.7 | 12.3 ± 5.7 | 0.008 |
LL post-ECMO (mmol/l) | 10.0 ± 5.4 | 6.4 ± 2.6 | 11.5 ± 5.6 | 0.003 |
LL postECMO- LL preECMO (mmol/l) | −0.9 ± 0.8 | −1.2 ± 0.6 | −0.9 ± 0.8 | 0.002 |
LC-1 6 h (mmol/l) | −1.8 ± 4.4 | −3.2 ± 1.1 | − 1.8 ± 4.4 | 0.017 |
LC-1 24 h (mmol/l) | −3.6 ± 5.6 | −4.6 ± 2.2 | − 3.6 ± 5.6 | 0.634 |
LC-1 48 h (mmol/l) | −2.9 ± 6.2 | −5.5 ± 2.6 | −2.9 ± 6.2 | 0.023 |
LC-2 (hours) | 7.0 ± 6.1 | 1.3 ± 1.3 | 9.4 ± 5.8 | < 0.001 |
Subgroups (The survivors versus Non-the survivors) refer to 30-day mortality. p-values calculated for comparison of the survivors versus non-the survivors by statistical analysis
Data are mean ± SD or n (%)
*Determined by Mann-Whitney U test or Spearman’s rho test
Abbreviations: ECMO extracorporeal membrane oxygenation, LL lactate level at specific time, LC-1 lactate clearance at specific time, LC-2 the duration between ECMO implantation time and time point that Lactate cleared more than 10% of the initial level